Divi’s Laboratories Gains 3.5% After Signing Long-Term Manufacturing and Supply Agreement with Global Pharma Major
Divi’s Laboratories rose 3.50% to ₹5,835.95 after announcing the signing of a long-term manufacturing and supply agreement with a leading global pharmaceutical company.
In a regulatory filing dated 18 April 2025, Divi’s stated that the agreement covers the manufacturing and supply of advanced intermediates. The partner’s identity remains confidential due to a non-disclosure clause. The company clarified that the agreement is international in scope and does not involve any upfront payments.
Divi’s expects a “meaningful revenue contribution” from the partnership over the duration of the agreement. To support this new business, the company plans to expand capacity at its manufacturing facilities, with an estimated investment of ₹650–700 crore, fully funded through internal accruals. The agreement is not classified as a related party transaction and aligns with Divi’s strategy to broaden its custom synthesis offerings.
Divi’s Laboratories specializes in the manufacturing of generic APIs, custom synthesis of active ingredients for innovator companies, specialty chemicals, and nutraceuticals, with a strong focus on export markets.
Financially, Divi’s reported a 64.53% jump in consolidated net profit to ₹589 crore, alongside a 25.01% increase in revenue from operations to ₹2,319 crore in Q3 FY25 compared to Q3 FY24.
